Ashpak Bangi
A5022257611- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Venous Thromboembolism Diagnosis and Management
Axis Multispecialty Hospital
2022-2024
Abstract Objective To determine whether disrupting the renin angiotensin system with receptor blockers will improve clinical outcomes in people covid-19. Design CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. Setting 17 hospital sites India and Australia. Participants were at least 18 years old, previously untreated blockers, laboratory confirmed diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who had been admitted to...
BACKGROUND: Optimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain. METHODS: In an open-label, adaptive platform trial, we randomly assigned adults Covid-19 to low-dose low-molecular-weight heparin or intermediate-dose plus aspirin. response external evidence, the aspirin intervention was discontinued and a therapeutic-dose arm added. The primary end point death requirement new organ support by day 28, analyzed Bayesian logistic model....
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin blocker, candesartan, improves clinical outcomes people COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals India. Participants Adults <65 years old intended for hospital admission moderate/severe COVID-19 disease (respiratory rate ≥24 breaths per minute or oxygen saturation ≤93% on room air)....